New Quaternary Ammonium Salts for use in Drug Manufacture

Informazioni relative al progetto

QuatSalts

ID dell’accordo di sovvenzione: 690882

DOI

10.3030/690882

Progetto chiuso

Data della firma CE 3 Novembre 2015

Data di avvio 1 Marzo 2016

Data di completamento 29 Febbraio 2020

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale

€ 774 000,00

Contributo UE

€ 774 000,00

Coordinato da

UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II
Italy

Periodic Reporting for period 2 - QuatSalts (New Quaternary Ammonium Salts for use in Drug Manufacture)

Periodo di rendicontazione: 2018-03-01 al 2020-02-29

Sintesi del contesto e degli obiettivi generali del progetto

The problem being addressed: The ability to develop more environmentally friendly ways of manufacturing pharmaceuticals


Why it's important for society: It is important so that pharmaceuticals can still be made, but with less harmful chemicals being employed in their manufacture which can have a deleterious impact on the environment


What are the overall objectives: To develop, test and implement new catalysts which enable the environmentally friendly manufacture of drugs

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

We have been involved in the design and synthesis of new families of ammonium salts organocatalysts (WP1) and peptide-based catalysts (WP2). We have also started a programme of evaluation of these catalysts.
So far we have successful made a number of these catalysts and they have given some promising results

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The catalysts which we are developing will advance the state of the art insofar as they will avoid the use of precious metals. They will also enable selectivity which is enhanced compared with other catalysts currently available on the market. In terms of the impact, the availability of these catalysts will enable new job creation, securing of existing jobs in Europe (which are under increasing pressure from lower wage economies in the pharmachem sector like India and China. In addition it will lead to new intellectual property which can be patented and might be the basis of formation of new companies.

image for publication